Mounjaro 12.5 mg

About this Medicine

Mounjaro 12.5 mg KwikPen offers an innovative approach for adults living with type 2 diabetes, providing an effective option for improving blood sugar control when used alongside a healthy diet and regular exercise. Its active ingredient, tirzepatide, acts as a dual agonist, targeting both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This unique mechanism allows Mounjaro to enhance the body's natural ability to produce insulin in response to high blood sugar, reduce the amount of glucose released by the liver, and slow gastric emptying, which collectively helps to lower A1C levels. Beyond its significant role in managing type 2 diabetes, Mounjaro 12.5 mg also serves as an important tool for chronic weight management. For adults with obesity (defined as a Body Mass Index, or BMI, of ≥30 kg/m²) or those who are overweight (BMI of 27 to <30 kg/m²) with at least one weight-related condition such as hypertension or high cholesterol, Mounjaro can aid in substantial weight loss. It achieves this by promoting a feeling of fullness and reducing hunger, leading to decreased calorie intake. The convenience of a once-weekly subcutaneous injection delivered via the KwikPen helps patients seamlessly integrate Mounjaro into their daily lives. It is crucial to remember that Mounjaro is a prescription medication and should only be used under the careful guidance of a healthcare professional. Your doctor will determine if Mounjaro is suitable for your individual health profile, provide precise instructions for use, and monitor your progress to ensure optimal outcomes for both your diabetes management and weight loss journey. Always discuss any questions or potential side effects with your healthcare provider.